TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24438342

Group type: EXPERIMENTAL
Intervention: Tailored support intervention by a diabetes nurse (home visits at 3 weeks, 2 weeks, and 2 months after discharge)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tailored support intervention by a diabetes nurse
Number of subjects: 200

Group type: COMPARATOR
Intervention: Consultation by telephone (control group)
Number of subjects: 200
Study: 24439297

Group type: EXPERIMENTAL
Intervention: AAV.REP1 (0·6-1·0×10(10) genome particles, subfoveal injection)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control eyes (not specified treatment)
Number of subjects: 6
Study: 24439931

Group type: EXPERIMENTAL
Intervention: Cixutumumab (20 mg/kg) administered intravenously every 3 weeks until disease progression or intolerable toxic effects
Number of subjects: 49
Study: 24439950

Group type: EXPERIMENTAL
Intervention: Frequency of marijuana use
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Frequency of alcohol use
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Interaction of marijuana by alcohol use frequency
Number of subjects: 332
Study: 24440085

Group type: EXPERIMENTAL
Intervention: LY2584702 75 mg BID
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: LY2584702 100 mg QD
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: LY2584702 (various doses)
Number of subjects: 34
Study: 24440112

Group type: EXPERIMENTAL
Intervention: 1-dose PCV7
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 2-dose PCV7
Number of subjects: 221

Group type: COMPARATOR
Intervention: PPV23
Number of subjects: 221
Study: 24440279

Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg twice daily continuously until disease progression or intolerable toxicity
Number of subjects: 64
Study: 24440330

Group type: EXPERIMENTAL
Intervention: Amigo Remote Catheter System (RCS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual ablation
Number of subjects: 50
Study: 24440471

Group type: EXPERIMENTAL
Intervention: Community based model for cervical cancer screening using self-sampling
Number of subjects: 8382
Study: 24441951

Group type: EXPERIMENTAL
Intervention: Soluble lutein/zeaxanthin 1 % and brilliant blue 0.025 %
Number of subjects: 18
Study: 24442098

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 6.25 mg/kg orally twice daily
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 7
Study: 24443249

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 0
Study: 24443277

Group type: EXPERIMENTAL
Intervention: Ofatumumab (doses ranging from 100 mg to 2000 mg)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 477
Study: 24443504

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation with an irrigated-tip contact force-sensing catheter in temperature-controlled mode (temperature limited to 48°C, power to 30 W)
Number of subjects: 15
Study: 24444305

Group type: EXPERIMENTAL
Intervention: B27+ media
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous human serum (aHS) and two different commercially available GMP AB HSs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GMP gamma-irradiated FBSs (giFBSs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B27 and selected giFBS
Number of subjects: 0
Study: 24444339

Group type: COMPARATOR
Intervention: Presence of at least 1 Ala-MnSOD allele (rs4880) in male subjects
Number of subjects: 110

Group type: COMPARATOR
Intervention: Presence of 2 G-eNOS allele (rs1799983) in both men and women
Number of subjects: 110
Study: 24444526

Group type: EXPERIMENTAL
Intervention: Oral epigallocatechin-3-gallate (EGCG) administered three times a day after the occurrence of grade 2 esophagitis, with dose escalation at six concentration levels.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral epigallocatechin-3-gallate (EGCG) administered three times a day after the occurrence of grade 2 esophagitis.
Number of subjects: 24
Study: 24444527

Group type: EXPERIMENTAL
Intervention: Individualised isotoxic accelerated radiotherapy (INDAR) with concurrent or sequential platinum-based chemotherapy.
Number of subjects: 83
Study: 24445082

Group type: EXPERIMENTAL
Intervention: WELCH questionnaire score
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: WELCH questionnaire
Number of subjects: 450
Study: 24445353

Group type: EXPERIMENTAL
Intervention: Okada purifying therapy (OPT), administered every weekday for 1 year by certified practitioners.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (regular patients at the clinic).
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Okada purifying therapy (OPT).
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Follow-up survey for those who continued using OPT regularly.
Number of subjects: 20
Study: 24445595

Group type: EXPERIMENTAL
Intervention: High-dose hemithoracic intensity-modulated radiation therapy (IMRT) followed by extrapleural pneumonectomy (EPP)
Number of subjects: 25
Study: 24446519

Group type: EXPERIMENTAL
Intervention: IL-15 stimulation of CD8(+) T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPS or HIV-1-activated dendritic cells (DCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DCs isolated from viremic HIV-1 patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of CD8(+) T cells to CD4(+) T cells
Number of subjects: 0
Study: 24446656

Group type: EXPERIMENTAL
Intervention: GIPR Glu354Gln (rs1800437) carriers (C allele)
Number of subjects: 1686

Group type: EXPERIMENTAL
Intervention: Homozygous for the variant C allele
Number of subjects: 1686
Study: 24446658

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) serum levels
Number of subjects: 1097
Study: 24447083

Group type: EXPERIMENTAL
Intervention: Higher doses of inhaled glucocorticosteroids (1700 μg)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Higher doses of oral glucocorticosteroids (6.7 mg)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Higher sputum eosinophils (25.7%)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Exhaled NO > 45 p.p.b.
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: History of smoking
Number of subjects: 169
Study: 24447458

Group type: EXPERIMENTAL
Intervention: Ultra-protective lung ventilation strategies during ECMO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation settings during ECMO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Airway pressure considerations during venoarterial ECMO support
Number of subjects: 0
Study: 24448848

Group type: EXPERIMENTAL
Intervention: DQIP intervention targeting high-risk prescribing of NSAIDs and antiplatelets
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: DQIP intervention targeting asthma control
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: DQIP intervention targeting antithrombotics in atrial fibrillation (AF)
Number of subjects: 4
Study: 24449032

Group type: EXPERIMENTAL
Intervention: Multi-modal intervention strategy
Number of subjects: 6066
Study: 24449167

Group type: EXPERIMENTAL
Intervention: Maltodextrins with glutamine (0.117 g kg(-1) h(-1))
Number of subjects: 5

Group type: COMPARATOR
Intervention: Maltodextrins alone (0.25 g kg(-1) h(-1), control)
Number of subjects: 5
Study: 24449368

Group type: EXPERIMENTAL
Intervention: NAFLD
Number of subjects: 2315

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2315
Study: 24449716

Group type: EXPERIMENTAL
Intervention: Early invasive strategy post-fibrinolysis with GPIIb/IIIa inhibitors
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Early invasive strategy post-fibrinolysis without GPIIb/IIIa inhibitors
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Standard therapy post-fibrinolysis with GPIIb/IIIa inhibitors
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Standard therapy post-fibrinolysis without GPIIb/IIIa inhibitors
Number of subjects: 1059
Study: 24450444

Group type: EXPERIMENTAL
Intervention: Early response to treatment (TCS ≤4 days)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Later response to treatment (TCS >4 days)
Number of subjects: 585
Study: 24452648

Group type: EXPERIMENTAL
Intervention: Pain Group (PG)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Surgical Group (SG)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Non-opioid analgesics (NSAIDs) in Pain Group (PG)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Non-opioid analgesics (NSAIDs) in Surgical Group (SG)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Other drugs in Pain Group (PG)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Other drugs in Surgical Group (SG)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Psychotropic drugs in Pain Group (PG)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Psychotropic drugs in Surgical Group (SG)
Number of subjects: 343
Study: 24452726

Group type: EXPERIMENTAL
Intervention: Implantation of two Glaukos Trabecular Micro-Bypass iStent inject devices
Number of subjects: 99
Study: 24452746

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg once daily for 14 days followed by a single dose of colchicine 0.6 mg co-administered with atorvastatin 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single oral dose of colchicine 0.6 mg
Number of subjects: 24
Study: 24452753

Group type: EXPERIMENTAL
Intervention: R2
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: R2*
Number of subjects: 51

Group type: COMPARATOR
Intervention: R2 and R2*
Number of subjects: 51
Study: 24455219

Group type: EXPERIMENTAL
Intervention: Second 200,000 IU capsule of vitamin A
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Base retinol level
Number of subjects: 276
Study: 24455283

Group type: EXPERIMENTAL
Intervention: Oncotype DX testing
Number of subjects: 225

Group type: COMPARATOR
Intervention: Tertiary referral centers
Number of subjects: 225

Group type: COMPARATOR
Intervention: Municipal hospital treatment
Number of subjects: 225
Study: 24455735

Group type: EXPERIMENTAL
Intervention: Paracervical block with ultracaine
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Lidocaine spray (2 puffs on cervical mucosa)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Oral dexketoprofen trometamol (25 mg)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1000 mg)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 111
Study: 24456220

Group type: EXPERIMENTAL
Intervention: Maternal antenatal melatonin administration via intravenous infusion until term
Number of subjects: 0

Group type: COMPARATOR
Intervention: IUGR alone (control group)
Number of subjects: 0
Study: 24456358

Group type: EXPERIMENTAL
Intervention: Nonanthocyanins from black soybean extract
Number of subjects: 0
Study: 24456586

Group type: EXPERIMENTAL
Intervention: Romidepsin 14 mg/m2 as a 4-hour intravenous infusion on days 1, 8, and 15 every 28 days for up to 6 cycles; patients with response or stable disease could continue beyond 6 cycles.
Number of subjects: 130
Study: 24456695

Group type: EXPERIMENTAL
Intervention: CAT score category 0-9
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAT score category 10-19
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAT score category 20-29
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAT score category 30-40
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exacerbation history (≥2 vs. 1 event in the past year)
Number of subjects: 0
Study: 24456794

Group type: EXPERIMENTAL
Intervention: LY2584702 (50-200mg) + erlotinib (150mg once daily)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: LY2584702 (50-200mg) + everolimus (10mg once daily)
Number of subjects: 29
Study: 24457244

Group type: EXPERIMENTAL
Intervention: GSK525762 (a novel, orally bioavailable bromodomain and extra terminal inhibitor)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Cisplatin, ifosfamide, and etoposide
Number of subjects: 1
Study: 24457280

Group type: EXPERIMENTAL
Intervention: Women undergoing primary PCI
Number of subjects: 8073

Group type: COMPARATOR
Intervention: Men undergoing primary PCI
Number of subjects: 8073
Study: 24457377

Group type: EXPERIMENTAL
Intervention: Src inhibition
Number of subjects: 0
Study: 24457379

Group type: EXPERIMENTAL
Intervention: Pertuzumab (840-mg loading dose and 420-mg maintenance intravenously every 3 weeks) and erlotinib (150-mg or 100-mg dose orally, daily)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pertuzumab and erlotinib
Number of subjects: 41
Study: 24457423

Group type: EXPERIMENTAL
Intervention: Thai-Five Minute Hearing Test (Thai-FMHT)
Number of subjects: 558
Study: 24458353

Group type: EXPERIMENTAL
Intervention: Circadian misalignment (bedtimes delayed by 8.5 h on 4 of the 8 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Circadian alignment (fixed nocturnal bedtimes)
Number of subjects: 26
Study: 24458437

Group type: EXPERIMENTAL
Intervention: VcR-CVAD induction chemoimmunotherapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Maintenance rituximab (MR)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 75
Study: 24458953

Group type: EXPERIMENTAL
Intervention: 18-FDG uptake (measured by target-to-background ratio, TBR)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Carotid wall area (WA) changes
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Total vessel area (TVA) changes
Number of subjects: 130
Study: 24459159

Group type: EXPERIMENTAL
Intervention: Self-reported autoimmune disease
Number of subjects: 0
Study: 24459219

Group type: EXPERIMENTAL
Intervention: Thiotepa and reduced-dose CYC
Number of subjects: 6
Study: 24459612

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 22
Study: 24460746

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 6610
Study: 24460974

Group type: EXPERIMENTAL
Intervention: Implementation of smoking cessation guidelines (5 A's framework)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cessation counseling by emergency nurses (ENs)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall perceptions of cessation counseling in the ED
Number of subjects: 30
Study: 24460975

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (15 ml) deposited above the femoral nerve (Group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (15 ml) deposited below the femoral nerve (Group B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (15 ml) deposited circumferential to the femoral nerve (Group C)
Number of subjects: 52
Study: 24461472

Group type: EXPERIMENTAL
Intervention: BMI <-2 SDS (moderate malnutrition)
Number of subjects: 2567

Group type: EXPERIMENTAL
Intervention: BMI <-3 SDS (severe malnutrition)
Number of subjects: 2567

Group type: EXPERIMENTAL
Intervention: BMI <-2 SDS
Number of subjects: 2567
Study: 24461715

Group type: EXPERIMENTAL
Intervention: Sweden
Number of subjects: 510863

Group type: COMPARATOR
Intervention: UK
Number of subjects: 510863

Group type: COMPARATOR
Intervention: UK vs Sweden
Number of subjects: 510863

Group type: COMPARATOR
Intervention: UK vs Sweden over time
Number of subjects: 510863
Study: 24462117

Group type: EXPERIMENTAL
Intervention: Modified RESIDential Environment physical activity questionnaire
Number of subjects: 152
Study: 24462171

Group type: EXPERIMENTAL
Intervention: Volumetric laser endomicroscopy (VLE) guided biopsy
Number of subjects: 22
Study: 24463454

Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg) single dose
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg) chronic treatment
Number of subjects: 66
Study: 24464121

Group type: EXPERIMENTAL
Intervention: Stabilized hyaluronic acid gel (HA)
Number of subjects: 61
Study: 24464355

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg/day on day 1 followed by 800 mg/day from day 2 onward
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pazopanib 1,000 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pazopanib plus lapatinib (400/1,000 mg, 800/1,000 mg, 400/1,500 mg, 600/1,250 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pazopanib monotherapy (800 mg and 1,000 mg) and pazopanib plus lapatinib (any doses)
Number of subjects: 27
Study: 24464597

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 85
Study: 24464944

Group type: EXPERIMENTAL
Intervention: Sustained blood oxygenation level-dependent responses in the superior temporal sulcus (STS) while observing facial expressions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Event-related changes in sustained MEG beta-band (14-30 Hz) oscillatory activity in the STS.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transient beta-band activity in sensorimotor cortex during viewing of fearful and happy expressions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of sustained STS beta-band activity with speed of emotion recognition.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valence-specific coupling of STS beta-band activity with facial movements.
Number of subjects: 0
Study: 24465046

Group type: EXPERIMENTAL
Intervention: 2.5 µg sufentanil plus 0.5% levobupivacaine (2.2 ± 0.2 mL)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 10 µg fentanyl plus 0.5% levobupivacaine (2.2 ± 0.2 mL)
Number of subjects: 93

Group type: COMPARATOR
Intervention: 0.5% levobupivacaine (2.2 ± 0.2 mL)
Number of subjects: 93
Study: 24465370

Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) for symptom scores
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Severe headache
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Correlation analysis of symptoms
Number of subjects: 292
Study: 24465444

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) with HIV-positive Peer Mentors; 4 antenatal and 4 postnatal meetings
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 1200
Study: 24465572

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 812

Group type: COMPARATOR
Intervention: Smear microscopy
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Liquid culture
Number of subjects: 812
Study: 24465663

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) for measuring retinal nerve fiber layer (RNFL) thickness in PD patients
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) for measuring RNFL thickness in PD patients
Number of subjects: 644
Study: 24467603

Group type: EXPERIMENTAL
Intervention: Genetic variants in the prostaglandin E2 pathway
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: rs4434423A in the PTGER4 gene
Number of subjects: 680
Study: 24467608

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Longer surgical procedures
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Postoperative pain incidence
Number of subjects: 206
Study: 24467767

Group type: EXPERIMENTAL
Intervention: CuidaCare intervention (standard care intervention in primary health care)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (standard care without CuidaCare intervention)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: CuidaCare intervention
Number of subjects: 142
Study: 24467979

Group type: EXPERIMENTAL
Intervention: Interleukin-10 treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 24467987

Group type: EXPERIMENTAL
Intervention: Stool substitute preparation made from purified intestinal bacterial cultures derived from a single healthy donor
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Stool substitute preparation
Number of subjects: 2
Study: 24469387

Group type: EXPERIMENTAL
Intervention: ELOPE Study (Evaluation of Long-term Outcomes after Pulmonary Embolism)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residual pulmonary vascular abnormalities on follow-up imaging and echocardiogram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial and/or residual clot burden, recurrent pulmonary embolism, altered pulmonary artery or right ventricular hemodynamics, or other prognostic factors such as biomarker levels
Number of subjects: 0
Study: 24470004

Group type: EXPERIMENTAL
Intervention: 12 weeks of 90-minute twice per week hatha yoga classes
Number of subjects: 200

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 200
Study: 24470398

Group type: EXPERIMENTAL
Intervention: ADPKD patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: ADPKD diagnosis
Number of subjects: 70
Study: 24470559

Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum
Number of subjects: 254
Study: 24471561

Group type: EXPERIMENTAL
Intervention: zone-model predictive control (zone-MPC) with health monitoring system (HMS)
Number of subjects: 12
Study: 24471651

Group type: EXPERIMENTAL
Intervention: MoCA (Montreal Cognitive Assessment)
Number of subjects: 194
Study: 24472814

Group type: EXPERIMENTAL
Intervention: High MDR1 transcript levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCR-ABL(IS) <28%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No mutation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 0
Study: 24473178

Group type: EXPERIMENTAL
Intervention: Endovascular therapy with assessment of collateral grade
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Endovascular therapy with robust angiographic collateral grade
Number of subjects: 331
Study: 24473509

Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive treatment (tenecteplase thrombolysis followed by percutaneous coronary intervention)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Patients who died
Number of subjects: 398

Group type: COMPARATOR
Intervention: Successful thrombolysis
Number of subjects: 398

Group type: COMPARATOR
Intervention: Final myocardial blush grade 3
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Global Registry of Acute Coronary Events score
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Final myocardial blush grade of 0-2
Number of subjects: 398
Study: 24474568

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day) with non-ritonavir HAART
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sunitinib (dose escalation from 25 mg/day to 50 mg/day) with ritonavir-based HAART
Number of subjects: 19